HomeCompareEYES vs BTI

EYES vs BTI: Dividend Comparison 2026

EYES yields 48.31% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EYES wins by $323.2K in total portfolio value
10 years
EYES
EYES
● Live price
48.31%
Share price
$4.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$360.9K
Annual income
$71,162.95
Full EYES calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — EYES vs BTI

📍 EYES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEYESBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EYES + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EYES pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EYES
Annual income on $10K today (after 15% tax)
$4,106.28/yr
After 10yr DRIP, annual income (after tax)
$60,488.51/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, EYES beats the other by $58,119.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EYES + BTI for your $10,000?

EYES: 50%BTI: 50%
100% BTI50/50100% EYES
Portfolio after 10yr
$199.3K
Annual income
$36,974.79/yr
Blended yield
18.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

EYES
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-1.9
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EYES buys
0
BTI buys
0
No recent congressional trades found for EYES or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEYESBTI
Forward yield48.31%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$360.9K$37.7K
Annual income after 10y$71,162.95$2,786.64
Total dividends collected$285.6K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: EYES vs BTI ($10,000, DRIP)

YearEYES PortfolioEYES Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$15,531$4,830.92$11,299$598.92+$4.2KEYES
2$23,630$7,012.02$12,794$703.91+$10.8KEYES
3$35,255$9,970.75$14,518$829.07+$20.7KEYES
4$51,625$13,902.68$16,513$978.64+$35.1KEYES
5$74,266$19,026.49$18,827$1,157.84+$55.4KEYES
6$105,044$25,579.93$21,518$1,373.12+$83.5KEYES
7$146,212$33,814.22$24,657$1,632.46+$121.6KEYES
8$200,433$43,987.07$28,329$1,945.74+$172.1KEYES
9$270,818$56,354.64$32,637$2,325.33+$238.2KEYES
10$360,939$71,162.95$37,708$2,786.64+$323.2KEYES

EYES vs BTI: Complete Analysis 2026

EYESStock

As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Full EYES Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this EYES vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EYES vs SCHDEYES vs JEPIEYES vs OEYES vs KOEYES vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.